ROCKVILLE, MD and SHENZHEN, CHINA, November 16, 2026 – HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented preclinical findings on HTD1801 in obesity management at ObesityWeek 2026, in Washington, D.C., US. The findings highlight the potential of HTD1801 to enhance weight loss in combination with GLP-1RAs and mitigate rebound following GLP-1RAs withdrawal.
HTD1801 is positioned to address multiple metabolic disorders by acting on the AMPK-NLRP3 axis to target both metabolic dysregulation and inflammation. Through this mechanism, it has demonstrated meaningful potential in weight management, with evidence supporting its role in reducing body weight while contributing to broader metabolic improvements. This study assessed the effects of HTD1801 in combination with GLP-1RAs on body weight reduction and body composition (including fat mass, lean body mass, and other components of body weight), and also evaluated whether HTD1801 could mitigate body weight regain after Semaglutide withdrawal.
Key findings include:
- Enhanced weight loss: HTD1801 in different dosing schedules demonstrated additional weight loss on top of semaglutide or tirzepatide.
- Improved weight loss quality and glycemic control: In combination with GLP-1RAs, HTD1801 enhances weight loss with improved weight loss quality and improved glycemic control.
- Reduced rebound after GLP-1RAs discontinuation: HTD1801 significantly attenuated body weight and blood glucose rebound after GLP-1RAs discontinuation, supporting its potential role in sustaining long-term weight control and maintenance treatment.
Based on these results, HTD1801 demonstrates great potential as a novel therapeutic option for weight management.
In a separate Phase IIa clinical trial in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM), 18 weeks of HTD1801 treatment led to notable weight loss (~3.5 kg), with an even greater reduction (~8 kg) observed in patients with hyperinsulinemia. Together, these clinical observations and preclinical findings support further clinical evaluation of HTD1801 as a novel therapeutic option for weight management.
Presentation Title: HTD1801 Add-On to Incretin-Based Agents Amplifies Weight Loss, Preserves Lean Mass and Curbs Rebound
Presentation Number: Poster-387
Date and Time: November 15, 2026, 2:30 PM–3:30 PM EST
Format: Poster Presentation
Presenter: Dr. Liping Liu, Founder, Chairperson, and CEO of HighTide Therapeutics
“Obesity management involves more than achieving weight loss; maintaining that weight loss while improving body composition and muscle strength are crucial considerations,” said Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics. “These findings suggest that, in combination with GLP-1RAs, HTD1801 may enhance weight loss, improve weight loss quality, while keep lean mass, and, attenuate body weight and blood glucose rebound following GLP-1RAs discontinuation. We look forward to further evaluating HTD1801’s potential to address unmet needs in obesity management and related CKM diseases.”
About HTD1801
HTD1801 is a first-in-class new molecular entity that targets the residual risks underlying cardiovascular–kidney–metabolic (CKM) diseases. It is an orally delivered, anti-inflammatory metabolic modulator (AIMM) that, as a single molecule, exerts its biological activity through the AMPK–NLRP3 axis, two complementary pathways that mitigate metabolic dysfunction. Multiple global clinical studies have demonstrated the comprehensive benefits of HTD1801, including improved insulin sensitivity, glycemic control, lipid lowering, renal protection, weight reduction, hepatic improvement, and anti-inflammatory effects. Collectively, these findings support the potential of HTD1801 to serve as a foundational therapy in CKM disease management.
About HighTide Therapeutics
HighTide Therapeutics, Inc. (2511.HK) is an innovative biopharmaceutical company dedicated to developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases. The company focuses on delivering breakthrough treatments that generate comprehensive, multi-organ benefits for patients worldwide. HighTide has built an innovative, globally integrated pipeline of proprietary assets and advanced multiple clinical programs across CKM diseases. The company’s lead asset, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the US Food and Drug Administration (FDA), and has been selected for China’s National Major Science and Technology Project for Significant New Drug Development.
For more information, please visit www.hightidetx.com. Contact: pr@hightidetx.com